미국의 마이크로어레이 시장 규모, 점유율, 동향 분석 리포트 : 제품·서비스별, 유형별, 용도별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Microarray Market Size & Trends:

The U.S. microarray market size was estimated at USD 2.65 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2033. The market is driven by the surging demand for personalized medicine, especially in precision oncology and pharmacogenomics. With rising investments from the NIH, universities, and biotech firms, microarrays are invaluable for identifying biomarkers, profiling gene expression, and tailoring therapeutic regimens-ultimately improving patient outcomes. In addition, the escalating prevalence of cancer and chronic diseases further enhances reliance on high-throughput genomic tools like microarrays for early detection and drug discovery.

Recent advancements in cancer research have significantly leveraged microarray instruments and reagents to enhance diagnostic accuracy and molecular profiling. Microarray platforms are increasingly used for gene expression profiling, allowing researchers to identify cancer-specific biomarkers, predict prognosis, and guide targeted therapies. In the U.S., companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina have introduced updated reagent kits optimized for high-throughput assays and low input RNA/DNA samples-critical for analyzing tumor biopsies. For instance, Thermo Fisher's GeneChip reagents support whole-transcriptome analysis in oncology research, while Agilent's SureTag DNA labeling kits enable robust hybridization for comparative genomic hybridization (CGH) in cancer cytogenetics. Illumina's Infinium assay kits, widely compatible with the iScan system, allow for simultaneous interrogation of methylation and SNP profiles, aiding in epigenetic cancer studies.

Growing investment and innovation in U.S.-based microarray technologies are poised to accelerate market growth, particularly in next-generation applications such as intradermal patch delivery. In March 2023, Vaxess Technologies, a Massachusetts-based biotech firm, secured an additional USD 9 million in funding to advance its MIMIX sustained-release intradermal microarray patch platform. This novel platform aims to revolutionize vaccine and therapeutic delivery by enabling self-administered, extended-release dosing through a skin patch. The funding, led by prominent U.S. investors such as RA Capital Management and The Engine (MIT's venture fund), will support ongoing clinical trials for influenza and COVID-19 vaccines and broaden the platform's applications into oncology, autoimmune diseases, and metabolic disorders.

Beyond healthcare, microarray technologies are gaining momentum in U.S. agriculture and environmental science. In precision farming, microarrays are used to decode plant genomes and identify traits that enhance resistance to pests and climate stressors, which are addressing U.S. food security challenges. Additionally, environmental agencies and academic institutions are increasingly using microarray-based toxicogenomic assays to evaluate the impact of pollutants on gene expression in local ecosystems. This multifaceted applicability-from clinical research to sustainability continues to expand the role of microarray instruments and reagents in driving innovation across sectors in the United States.

U.S. Microarray Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. microarray market report based on products and services, type, application, and end use.

• Product and Services Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Software and Services
• Instruments
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Microarrays
• Protein Microarrays
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Research Applications
• Drug Discovery
• Disease Diagnostics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product and Services
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Services Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Microarray Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for personalized medicine and genomic research
    • 3.2.1.2. Technological advancements in microarray platforms
    • 3.2.1.3. Expanding applications in diagnostics and infectious disease testing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of microarray instruments and consumables
• 3.3. U.S. Microarray Market Analysis Tools
  • 3.3.1. Industry Analysis Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Microarray Market: Product and Services Estimates & Trend Analysis

• 4.1. Product and Services Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Microarray Market by Product and Services Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Consumables
    • 4.4.1.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Software and Services
    • 4.4.3.1. Software and services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Microarray Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Microarray Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. DNA Microarray
    • 5.4.1.1. DNA Microarray market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Protein Microarray
    • 5.4.2.1. Protein microarray market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Others
    • 5.4.3.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Microarray Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Microarray Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Research applications
    • 6.4.1.1. Research application market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Drug discovery
    • 6.4.2.1. Drug discovery market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Disease diagnostics
    • 6.4.3.1. Disease diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Others application market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Microarray Market: End use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2033
• 7.2. Segment Dashboard
• 7.3. U.S. Microarray Market by End use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.4.1. Research and Academic Institutes
    • 7.4.1.1. Research and Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Pharmaceutical and Biotechnology Companies
    • 7.4.2.1. Pharmaceutical and Biotechnology Companies market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Diagnostic Laboratories
    • 7.4.3.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Thermo Fisher Scientific Inc (Applied Biosystems)
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Services benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Agilent Technologies, Inc
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Services benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Illumina, Inc
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Services benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. PerkinElmer
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Services benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Merck KGaA
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Services benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Schott (Applied Microarrays)
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Services benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Danaher Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Services benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Arrayit Corporation
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Services benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Bio-Rad Laboratories, Inc
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Services benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Microarrays Inc
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Services benchmarking
    • 8.4.10.4. Strategic initiatives